WO2024254841A1 - 化合物治疗疾病的方法及其用途 - Google Patents

化合物治疗疾病的方法及其用途 Download PDF

Info

Publication number
WO2024254841A1
WO2024254841A1 PCT/CN2023/100595 CN2023100595W WO2024254841A1 WO 2024254841 A1 WO2024254841 A1 WO 2024254841A1 CN 2023100595 W CN2023100595 W CN 2023100595W WO 2024254841 A1 WO2024254841 A1 WO 2024254841A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
amount
topical therapeutic
total weight
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/100595
Other languages
English (en)
French (fr)
Inventor
马振坤
王唤
贺世杰
耿国柱
张玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TenNor Therapeutics (Suzhou) Ltd
Original Assignee
TenNor Therapeutics (Suzhou) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TenNor Therapeutics (Suzhou) Ltd filed Critical TenNor Therapeutics (Suzhou) Ltd
Priority to JP2025572332A priority Critical patent/JP2026521250A/ja
Priority to CN202380099437.2A priority patent/CN121419767A/zh
Priority to PCT/CN2023/100595 priority patent/WO2024254841A1/zh
Priority to EP23941076.4A priority patent/EP4729057A4/en
Publication of WO2024254841A1 publication Critical patent/WO2024254841A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present application relates to the field of biomedicine, and specifically to a method for preventing or treating a disease with a compound and its use.
  • Diabetic foot infection is one of the serious complications of diabetes and the main cause of lower limb amputation in diabetic patients. Among the approximately 150 million diabetic patients worldwide, 15% to 20% of patients may develop foot ulcers or gangrene during their disease course. The amputation rate of diabetic foot disease is 15 times that of non-diabetic patients, and about 50% of the amputees each year are diabetic patients. The treatment of diabetic foot ulcers is extremely expensive, and its incidence in China has also shown a significant year-on-year increase. Therefore, the medical and social problems caused by diabetic foot infection have begun to receive attention from many domestic professionals.
  • the treatment of diabetic foot infection is often hindered by local ischemia, and systemic administration of antibiotics can sometimes only achieve low plasma levels of antibiotic drugs at the site of infection.
  • drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA)
  • MRSA methicillin-resistant Staphylococcus aureus
  • drugs for treating diabetic foot infections generally use oral or injectable cephalosporins, penicilliums, vancomycins and other antibiotics and anti-inflammatory drugs, which have the following disadvantages: large toxic side effects, or very easy to develop drug resistance, some patients have severe allergic reactions, etc. Therefore, it is particularly urgent and important to improve the treatment of diabetic foot infections, especially in cases of infection with specific drug-resistant bacteria and/or in cases where patients suffer from severe local ischemia and/or bone tissue is affected.
  • the present invention provides a more practical and effective treatment method.
  • the present application provides a method for preventing or treating diabetic foot infection (DFI), or alleviating the DFI-related symptoms, the method comprising administering a topical therapeutic agent to a patient in need thereof, the topical therapeutic agent comprising a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof, and the DFI is caused by Gram-positive bacterial infection,
  • the Gram-positive bacteria include drug-resistant strains thereof.
  • the topical therapeutic agent is an ointment formulation.
  • the topical therapeutic agent further comprises one or more of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizer, and an antioxidant.
  • the topical therapeutic agent consists of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizer, an antioxidant, and a compound of formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
  • the amount of the compound of formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product is about 0.3% to about 0.7% of the total mass of the topical therapeutic agent.
  • the amount of polyethylene glycol 400 is about 55% to about 60% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 3350 is about 28% to about 33% of the total weight of the topical therapeutic agent.
  • the amount of propylene glycol is about 8% to about 12% of the total weight of the topical therapeutic agent.
  • the solubilizing agent is used in an amount of about 0.1% to about 1% of the total mass.
  • the antioxidant is used in an amount of about 0.5% to about 1% of the total weight.
  • the topical therapeutic agent is composed of the following components: based on the total weight percentage of 100%, the amount of the compound represented by formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product accounts for about 0.3% to about 0.7% of the total weight of the topical therapeutic agent, the amount of polyethylene glycol 400 accounts for about 55% to about 60% of the total weight of the topical therapeutic agent, and the amount of polyethylene glycol 3350 accounts for about 10% to about 20% of the total weight of the topical therapeutic agent.
  • the amount of the propylene glycol is about 8% to about 12% of the total mass of the topical therapeutic agent, the amount of the solubilizer is about 0.1% to about 1% of the total mass of the topical therapeutic agent, and the amount of the antioxidant is about 0.5% to about 1% of the total mass of the topical therapeutic agent.
  • the method comprises administering the topical therapeutic agent to the patient in need thereof at a dosing frequency selected from once every 3 days, once every 2 days, once a day, and twice a day.
  • the diabetic foot infection is caused by Staphylococcus aureus infection and/or coagulase-negative Staphylococcus infection.
  • the Staphylococcus aureus comprises a resistant strain thereof, and the coagulase-negative Staphylococcus comprises a resistant strain thereof.
  • the method further comprises administering to the patient in need thereof an effective amount of an additional therapeutic agent.
  • the present application provides the use of a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof in the preparation of an external therapeutic agent, wherein the external therapeutic agent is used to prevent or treat diabetic foot infection (DFI) or alleviate the DFI-related symptoms, and the DFI is caused by Gram-positive bacterial infection; wherein the external therapeutic agent comprises a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
  • DFI diabetic foot infection
  • the external therapeutic agent comprises a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
  • the Gram-positive bacteria include drug-resistant strains thereof.
  • the topical therapeutic agent is an ointment formulation.
  • the topical therapeutic agent further comprises one or more of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizer, and an antioxidant.
  • the topical therapeutic agent consists of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizer, an antioxidant, and a compound of formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
  • the amount of the compound of formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product is about 0.3% to about 0.7% of the total mass of the topical therapeutic agent.
  • the amount of polyethylene glycol 400 is about 55% to about 60% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 3350 is about 28% to about 33% of the total weight of the topical therapeutic agent.
  • the amount of propylene glycol is about 8% to about 12% of the total weight of the topical therapeutic agent.
  • the solubilizing agent is used in an amount of about 0.1% to about 1% of the total mass.
  • the antioxidant is used in an amount of about 0.5% to about 1% of the total weight.
  • the topical therapeutic agent is composed of the following components: based on the total weight percentage being 100%, the amount of the compound represented by formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product is about 0.3% to about 0.7% of the total weight of the topical therapeutic agent, the amount of polyethylene glycol 400 is about 55% to about 60% of the total weight of the topical therapeutic agent, the amount of polyethylene glycol 3350 is about 28% to about 33% of the total weight of the topical therapeutic agent, the amount of propylene glycol is about 8% to about 12% of the total weight of the topical therapeutic agent, the amount of the solubilizer is about 0.1% to about 1% of the total weight of the topical therapeutic agent, and the amount of the antioxidant is about 0.5% to about 1% of the total weight of the topical therapeutic agent.
  • the topical therapeutic agent is formulated for administration to a patient in need thereof at a dosing frequency selected from once every 3 days, once every 2 days, once a day, and twice a day.
  • the diabetic foot infection is caused by Staphylococcus aureus infection and/or coagulase-negative Staphylococcus infection.
  • the Staphylococcus aureus comprises a resistant strain thereof, and the coagulase-negative Staphylococcus comprises a resistant strain thereof.
  • the topical therapeutic agent is formulated to be co-administered to the patient in need thereof with an effective amount of another therapeutic agent.
  • the term "patient in need” generally includes human patients and other mammalian subjects receiving preventive or therapeutic treatment, including but not limited to non-human primates, experimental animals such as rabbits, dogs, rats and mice, and other animals. These "patients in need” can be exemplarily subjects with confirmed specific diseases, subjects receiving treatment related to specific diseases, subjects with a tendency or risk of developing specific diseases, etc.
  • administering generally refers to introducing the drug or a composition comprising the drug (e.g., a therapeutic agent of the present application) into the patient's body by any introduction or delivery route. Any method known to those skilled in the art for contacting cells, organs or tissues with the drug or its composition can be used.
  • the term "therapeutic agent” generally refers to an agent that, when properly administered to a patient, is capable of inducing a desired therapeutic effect, preventing A compound, a mixture of compounds, a composition, a biomacromolecule or an extract made from biological materials that produces a certain disease or alleviates a related disease.
  • the term "pharmaceutically acceptable salt” generally refers to conventional acid- or base-addition salts that retain the biological efficacy and properties of the parent compound (e.g., the compound shown in formula (I)).
  • acid-addition salts can be formed by suitable non-toxic organic or inorganic acids
  • sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, aminosulfonic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, methanesulfonic acid, ethanesulfonic acid, trifluoroacetic acid, etc.
  • base-addition salts include salts such as sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts and magnesium salt
  • solvate and “solvate” are used interchangeably and generally refer to an association or complex of one or more solvent molecules and a salt-type compound of the present application.
  • solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
  • hydrate generally refers to a complex in which the solvent molecule is water.
  • prodrug generally refers to the prodrug substance that can be metabolized to form a substance having the structure of the compound of the present application after being administered to a patient
  • metabolite generally refers to the substance obtained by the metabolism of the compound of the present application after being administered to a patient, and the prodrugs and metabolites contained in such derivatives are included in the scope of the invention of the present application.
  • deuterated substance and “deuterated compound” are used interchangeably, and generally refer to a new compound obtained after one or more hydrogen atoms in an organic compound are replaced by deuterium atoms.
  • the term "ointment preparation” generally refers to a uniform semi-solid topical preparation made by mixing a drug with an oily or water-soluble matrix. It can be divided into a solution-type ointment and a suspension-type ointment because of the different dispersion states of the drug in the matrix, wherein the solvent-type ointment is an ointment formulation made by dissolving or co-dissolving the drug in the matrix or matrix components, and the suspension-type ointment is an ointment formulation made by uniformly dispersing the drug fine powder in the matrix.
  • the ointment preparation provided in the present application is generally used for external use and local treatment.
  • the drug in the ointment preparation can exert a systemic pharmacological or therapeutic effect after transdermal absorption.
  • the matrix of the ointment formulation as an excipient and drug carrier, can have an important impact on the quality of the ointment and the release and absorption of the drug.
  • the matrix of the ointment formulation commonly used in the art can be divided into an oily matrix, an emulsion matrix and a water-soluble matrix.
  • the ointment formulation required for the treatment method of the present application can be obtained by using a preparation method and process suitable in the art.
  • selected from generally refers to including selected objects and all combinations thereof.
  • selected from (:) A, B and C means including all combinations of A, B and C, for example, A, B, C, A+B, A+C, B+C or A+B+C.
  • the term "effective amount” or “effective dose” is used interchangeably, generally refers to an amount sufficient to obtain or at least partially obtain the desired therapeutic effect, and when used for a patient in need, it generally refers to an amount sufficient to cure an already sick patient or at least partially prevent the disease and its complications.
  • the effective amount for this use will depend on the severity of the patient's infection and the overall state of the patient's own immune system.
  • co-administration generally refers to the administration of the therapeutic agent described herein with other therapeutic agents or drugs as a single formulation or as multiple independent formulations. Co-administration can be performed simultaneously or sequentially in any order, for example, it can be preferably continued for a certain period of time when two (or all) active pharmaceutical ingredients exert their biological activities simultaneously.
  • the therapeutic agent of the present application and other therapeutic agents are not necessarily administered by the same route of administration.
  • the term "about” or “approximately” is generally within an acceptable error range for a particular value determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system.
  • “about” or “approximately” may mean within 1 or more than 1 standard deviation according to the practice of the art.
  • “about” or “approximately” may mean a range of up to 10% or 20% (i.e., ⁇ 10% or ⁇ 20%).
  • about 3 mg may include any amount between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%).
  • the term may mean a value of up to one order of magnitude or a value of up to 5 times.
  • the present application provides a method for preventing or treating diabetic foot infection (DFI), or alleviating the DFI-related conditions, the method comprising administering a topical therapeutic agent to a patient in need thereof, the topical therapeutic agent comprising a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof, and the DFI is caused by Gram-positive bacterial infection.
  • the Gram-positive bacteria may include drug-resistant strains thereof.
  • the diabetic foot infection is caused by Staphylococcus aureus infection and/or coagulase-negative Staphylococcus infection.
  • Staphylococcus aureus may also include its resistant strains
  • the coagulase-negative Staphylococcus may also include its resistant strains.
  • the coagulase-negative Staphylococcus may be selected from Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus xylinus, Staphylococcus capitis, Staphylococcus warneri, Staphylococcus mimicus, Staphylococcus xylosus and Staphylococcus apes.
  • the resistant strain may be resistant to rifamycin (e.g., rifampicin), resistant to quinolones or quinolones, or resistant to rifamycin and quinolones.
  • the resistant strain may also be resistant to The strains are resistant to other antibiotics, including those to macrolides such as clarithromycin, azithromycin, and roxithromycin; to nitroimidazoles such as metronidazole, ornidazole, premanide, and delamanide; to aminoglycosides such as streptomycin and amikacin; to ⁇ -lactams such as methicillin, ampicillin, and amoxicillin; to tetracyclines such as tetracycline, tigecycline, and minocycline; to oxazolidinones such as linezolid and tedizolid; to nitrofurans such as furazolidone; to polypeptides such as vancomycin and polymyxin; to diarylquinolines such as bedaquiline and clofazimine, etc.
  • macrolides such as clarithromycin, azithromycin, and roxithromycin
  • nitroimidazoles such as metronidazole, orni
  • the topical therapeutic agent may be an ointment formulation.
  • the topical therapeutic agent further comprises one or more of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizing agent and an antioxidant.
  • the topical therapeutic agent is composed of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizing agent, an antioxidant, and a compound shown in formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance.
  • the solubilizing agent described in the present application may include triethanolamine.
  • the antioxidant described in the present application may include vitamin C, vitamin E or a combination thereof.
  • the compound of formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance is used in an amount of about 0.3% to about 0.7% of the total mass of the topical therapeutic agent.
  • the compound of formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance is used in an amount of about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.65% or about 0.70% of the total mass of the topical therapeutic agent.
  • the amount of polyethylene glycol 400 is about 55% to about 60% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 400 is about 55%, about 56%, about 57%, about 58%, about 59% or about 60% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 3350 is about 28% to about 33% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 3350 is about 28%, about 29%, about 30%, about 31%, about 32% or about 33% of the total weight of the topical therapeutic agent.
  • the amount of propylene glycol is about 8% to about 12% of the total mass of the topical therapeutic agent.
  • the amount of propylene glycol is about 8.0%, about 8.5%, about 9.0%, about 9.5%, about 10.0%, about 10.5%, about 11.0%, about 11.5%, or about 12.0% of the total mass of the topical therapeutic agent.
  • the solubilizing agent is used in an amount of about 0.1% to about 1% of the total mass.
  • the solubilizing agent is used in an amount of about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.90%, about 0.95% or about 1.00% of the total mass.
  • the antioxidant is used in an amount of about 0.5% to about 1% of the total mass.
  • the antioxidant is used in an amount of about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.90%, about 0.95% or about 1.00% of the total mass.
  • the topical therapeutic agent is composed of the following components: based on the total weight percentage being 100%, the amount of the compound represented by formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof accounts for about 0.3% to about 0.7% (e.g., about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.76%, about 0.77%, about 0.78%, about 0.79%, about 0.80%, about 0.81%, about 0.82%, about 0.83%, about 0.84%, about 0.86%, about 0.87%, about 0.88%, about 0.89%, about 0.90%, about 10.10%, about 10.20%, about 10.30%, about 10.40%, about 10.50%, about 10.60%, about 10.75%, about 10.86%, about 0.87%, about 0.88%, about
  • the amount of polyethylene glycol 400 is about 55% to about 60% (e.g., about 55%, about 56%, about 57%, about 58%, about 59% or about 60%) of the total weight of the topical therapeutic agent
  • the amount of polyethylene glycol 3350 is about 28% to about 33% (e.g., about 28%, about 29%, about 30%, about 31%, about 32% or about 33%) of the total weight of the topical therapeutic agent
  • the amount of propylene glycol is about 8% to about 10% of the total weight of the topical therapeutic agent.
  • the amount of the solubilizer is about 0.1% to about 1% (e.g., about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.70%, about 0.80%, about 0.90%, about 10.10%, about 11.0%, about 11.5%, or about 12.0%) of the total weight of the topical therapeutic agent.
  • the amount of the antioxidant is about 0.5% to about 1% (for example, about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.90%, about 0.95% or about 1.00%) of the total weight of the topical therapeutic agent.
  • the method comprises administering the topical therapeutic agent to the patient in need thereof at a dosing frequency selected from once every 3 days, once every 2 days, once a day, and twice a day.
  • the method further comprises administering an effective amount of other therapeutic agents to the patient in need.
  • the method further comprises administering an effective amount of other therapeutic agents to the patient by injection (e.g., intravenous injection, intramuscular injection and/or subcutaneous injection), oral administration, intracavitary administration, enteral administration and/or transdermal absorption.
  • the other therapeutic agents can be selected from antibacterial agents, anesthetics, analgesics, sedatives, hormone drugs, anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors, antipyretics, cell membrane permeation agents and muscle relaxants, etc.
  • the present application provides the use of a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance thereof in the preparation of an external therapeutic agent, wherein the external therapeutic agent is used to prevent or treat diabetic foot infection (DFI) or alleviate the DFI-related conditions, and the DFI is caused by Gram-positive bacteria infection; wherein the external therapeutic agent comprises a compound represented by formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance thereof.
  • the Gram-positive bacteria comprise drug-resistant strains thereof.
  • the diabetic foot infection is caused by Staphylococcus aureus and/or coagulase-negative Staphylococci. Infection causes.
  • the Staphylococcus aureus may also include its resistant strains
  • the coagulase-negative Staphylococcus may also include its resistant strains.
  • the coagulase-negative Staphylococcus may be selected from Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus xylinus, Staphylococcus haemolyticus, Staphylococcus capitis, Staphylococcus warneri, Staphylococcus mimicus, Staphylococcus xylosus and Staphylococcus apes.
  • the resistant strain may be resistant to rifamycin (e.g., rifampicin) single resistance, resistant to quinolone or quinolones single resistance or resistant to rifamycin and quinolones double resistance.
  • the resistant strains may also be resistant to other antibiotics, including resistance to macrolide drugs such as clarithromycin, azithromycin, roxithromycin, etc.; resistance to nitroimidazole drugs such as metronidazole, ornidazole, premanid, delamanid, etc.; resistance to aminoglycoside drugs such as streptomycin, amikacin, etc.; resistance to ⁇ -lactam drugs such as methicillin, ampicillin, amoxicillin, etc.; resistance to tetracycline drugs such as tetracycline, tigecycline, minocycline, etc.; resistance to oxazolidinone drugs such as linezolid, tedizolid, etc.; resistance to nitrofuran drugs such as furazolidone, etc.; resistance to polypeptide drugs such as vancomycin, polymyxin, etc.; resistance to diarylquinoline drugs such as bedaquiline and clofazimine, etc.
  • macrolide drugs such as clarithro
  • the topical therapeutic agent may be an ointment formulation.
  • the topical therapeutic agent further comprises one or more of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizing agent and an antioxidant.
  • the topical therapeutic agent is composed of polyethylene glycol 400, polyethylene glycol 3350, propylene glycol, a solubilizing agent, an antioxidant, and a compound shown in formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance.
  • the solubilizing agent described in the present application may include triethanolamine.
  • the antioxidant described in the present application may include vitamin C, vitamin E or a combination thereof.
  • the compound of formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance is used in an amount of about 0.3% to about 0.7% of the total mass of the topical therapeutic agent.
  • the compound of formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance is used in an amount of about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.65% or about 0.70% of the total mass of the topical therapeutic agent.
  • the amount of polyethylene glycol 400 is about 55% to about 60% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 400 is about 55%, about 56%, about 57%, about 58%, about 59% or about 60% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 3350 is about 28% to about 33% of the total weight of the topical therapeutic agent.
  • the amount of polyethylene glycol 3350 is about 28%, about 29%, about 30%, about 31%, about 32% or about 33% of the total weight of the topical therapeutic agent.
  • the amount of propylene glycol is about 8% to about 12% of the total weight of the topical therapeutic agent.
  • the amount of propylene glycol is about 8.0%, about 8.5%, about 9.0%, about 9.5%, about 10.0%, about 10.5%, about 11.0%, about 11.5% or about 12.0%.
  • the solubilizing agent is used in an amount of about 0.1% to about 1% of the total mass.
  • the solubilizing agent is used in an amount of about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.90%, about 0.95% or about 1.00% of the total mass.
  • the antioxidant is used in an amount of about 0.5% to about 1% of the total mass.
  • the antioxidant is used in an amount of about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.90%, about 0.95% or about 1.00% of the total mass.
  • the topical therapeutic agent is composed of the following components: based on the total weight percentage being 100%, the amount of the compound represented by formula (I) and/or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof accounts for about 0.3% to about 0.7% (e.g., about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.76%, about 0.77%, about 0.78%, about 0.79%, about 0.80%, about 0.81%, about 0.82%, about 0.83%, about 0.84%, about 0.86%, about 0.87%, about 0.88%, about 0.89%, about 0.90%, about 10.10%, about 10.20%, about 10.30%, about 10.40%, about 10.50%, about 10.60%, about 10.75%, about 10.86%, about 0.87%, about 0.88%, about
  • the amount of polyethylene glycol 400 is about 55% to about 60% (e.g., about 55%, about 56%, about 57%, about 58%, about 59% or about 60%) of the total weight of the topical therapeutic agent
  • the amount of polyethylene glycol 3350 is about 28% to about 33% (e.g., about 28%, about 29%, about 30%, about 31%, about 32% or about 33%) of the total weight of the topical therapeutic agent
  • the amount of propylene glycol is about 8% to about 10% of the total weight of the topical therapeutic agent.
  • the amount of the solubilizer is about 0.1% to about 1% (e.g., about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, about 0.50%, about 0.55%, about 0.60%, about 0.70%, about 0.80%, about 0.90%, about 10.10%, about 11.0%, about 11.5%, or about 12.0%) of the total weight of the topical therapeutic agent.
  • the amount of the antioxidant is about 0.5% to about 1% (for example, about 0.50%, about 0.55%, about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.90%, about 0.95% or about 1.00%) of the total weight of the topical therapeutic agent.
  • the topical therapeutic agent is formulated for administration to a patient in need thereof at a dosing frequency selected from once every 3 days, once every 2 days, once a day, and twice a day.
  • the topical therapeutic agent is formulated to be suitable for co-administration with an effective amount of other therapeutic agents to the patient in need.
  • the topical therapeutic agent can be formulated to be suitable for co-administration with an effective amount of other therapeutic agents to the patient in need, wherein the other therapeutic agent can be administered by injection (e.g., intravenous injection, intramuscular injection and/or subcutaneous injection), oral administration, intracavitary administration, enteral administration and/or transdermal absorption to the patient.
  • the other therapeutic agent can be selected from antibacterial agents, anesthetics, analgesics, sedatives, hormone drugs, anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors, antipyretics, cell membrane permeation agents and muscle relaxants, etc.
  • test strains This example collected foot specimens from 49 patients with type II diabetes. From the above specimens, isolated strains were obtained by homogenization, plating, and culturing at 37°C, and fungi, strains with poor growth or strains that could not be separated and purified were removed. A total of 69 clinical strains were obtained, including 55 Gram-positive bacteria and 14 Gram-negative bacteria; among Gram-positive bacteria, there were 43 Staphylococci, 18 Staphylococcus aureus, 8 Staphylococcus epidermidis, and 5 Staphylococcus lugdunensis. Another ATCC standard strain was taken as a standard and quality control strain.
  • Preparation of biofilm In a sterile environment, use an inoculation loop to pick up a single colony that has been identified and revived, and prepare a bacterial suspension with a 0.5 McFarland turbidity unit as the initial inoculation bacterial suspension. Dilute the initial inoculation bacterial suspension 1:200: add 50 ⁇ L of the initial inoculation bacterial suspension to 10mL CAMHB medium. Use a pipette to transfer 150 ⁇ L of the inoculation bacterial suspension to the CBD plate, and place the inoculated CBD plate in an incubator at 35 ⁇ 2°C for 16 to 20 hours.
  • Antibacterial activity determination The standard broth dilution method and the in vitro biofilm culture and drug sensitivity methods reported in the literature were used to evaluate the minimum inhibitory concentration (MIC) and the minimum biofilm clearance concentration (MBBC) of the compound of formula (I) and the control drug (see 2 for details) against 69 clinical strains of diabetic foot infection isolated from the clinic.
  • MIC minimum inhibitory concentration
  • MBBC minimum biofilm clearance concentration
  • Table 1-1 show that the compound of formula (I) has significantly better antibacterial activity against Gram-positive bacterial isolates than against Gram-negative bacteria.
  • Its MIC 50 and MIC 90 are ⁇ 0.015 ⁇ g/mL and 0.25 ⁇ g/mL, respectively, and are significantly better than the first-line clinical drugs linezolid (MIC 50 and MIC 90 are 2 ⁇ g/mL and 4 ⁇ g/mL, respectively) and vancomycin (MIC 50 and MIC 90 are both 2 ⁇ g/mL);
  • the MBBC results of the compound of formula (I) also prove that it has better bactericidal activity against Gram-positive bacterial biofilm in vitro than against Gram-negative bacteria.
  • MBBC 50 and MBBC 90 are 0.125 ⁇ g/mL and 16 ⁇ g/mL, respectively, which are significantly better than the first-line clinical drugs linezolid (MBBC 50 and MBBC 90 are both >128 ⁇ g/mL) and vancomycin (MBBC 50 and MBBC 90 are both >128 ⁇ g/mL). 90 %>128 ⁇ g/mL).
  • the results in Table 1-2 show that the compound of formula (I) has an effective effect on Staphylococci (including Staphylococcus aureus and Staphylococcus epidermidis) in The compounds of formula (I) have good antibacterial activity against isolates of Staphylococcus aureus (S. aureus), and their MIC ranges are ⁇ 0.015-0.25 ⁇ g/mL, ⁇ 0.015-0.03 ⁇ g/mL and ⁇ 0.015-0.03 ⁇ g/mL, respectively.
  • the MIC 50 of the compounds of formula (I) against Staphylococcus aureus and Staphylococcus aureus are both ⁇ 0.015 ⁇ g/mL, which is significantly better than linezolid (MIC 50 is both 2 ⁇ g/mL) and vancomycin (MIC 50 is both 2 ⁇ g/mL); their MIC 90 are all ⁇ 0.015 ⁇ g/mL, which is significantly better than linezolid (MIC 90 is both 4 ⁇ g/mL) and vancomycin (MIC 90 is both 2 ⁇ g/mL).
  • Tables 1-3 show that the compounds of formula (I) have good bactericidal activity against in vitro biofilms of Staphylococci (including Staphylococcus aureus and Staphylococcus epidermidis), and their MBBC ranges are ⁇ 0.015-1 ⁇ g/mL, 0.03-0.5 ⁇ g/mL and ⁇ 0.015-0.06 ⁇ g/mL, respectively.
  • the MBBC 50 of the compounds of formula (I) against Staphylococcus aureus and Staphylococcus aureus are 0.06 ⁇ g/mL and 0.25 ⁇ g/mL, respectively, which are significantly better than linezolid (MBBC 50 is >128 ⁇ g/mL) and vancomycin (MBBC 50 is >128 ⁇ g/mL); their MBBC 90 is 0.5 ⁇ g/mL, which is significantly better than linezolid (MBBC 90 is >128 ⁇ g/mL) and vancomycin (MBBC 90 is >128 ⁇ g/mL).
  • the compound of formula (I) has good antibacterial and bactericidal activity against Gram-positive bacteria and staphylococcal isolates (including Staphylococcus aureus and Staphylococcus epidermidis) among Gram-positive bacteria and in vitro biofilms, and the antibacterial and bactericidal activities are significantly better than those of the clinical first-line drugs linezolid and vancomycin, and it has potential clinical advantages in the treatment of diabetic foot infection.
  • a stable mouse skin infection model was constructed using S. aureus NRS 384 to evaluate the antibacterial activity of the ointment containing the compound of formula (I) described in the present application on the skin surface.
  • a total of 6 groups were set up, namely: a blank control group (with 4 hours after infection as the experimental endpoint), a solvent group, a Bactroban ointment group, and an ointment group containing three doses of the compound of formula (I) at low, medium, and high doses.
  • Each of the above groups had 8 animals, and the specific experimental settings were as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请提供了一种预防或治疗糖尿病足感染(DFI)、或者减轻所述DFI相关病症的方法，所述方法包括向有需要的患者施用外用治疗剂，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物，且所述DFI由革兰氏阳性菌感染引起，

Description

化合物治疗疾病的方法及其用途 技术领域
本申请涉及生物医药领域，具体的涉及一种化合物预防或治疗疾病的方法及其用途。
背景技术
糖尿病足感染(DFI)是糖尿病患者严重的并发症之一，是糖尿病患者下肢截肢的主要原因。全球约1.5亿糖尿病患者中，有15％～20％的患者可能在其病程中发生足溃疡或坏疽。糖尿病足病的截肢率是非糖尿病患者的15倍，每年的截肢患者中约50％是糖尿病患者。糖尿病足溃疡的治疗花费巨大，其在中国的发病率也呈明显的逐年增加趋势，因此，糖尿病足感染所带来的医学和社会问题已开始受到国内诸多学者的重视。糖尿病足感染的治疗经常受到局部缺血的阻碍，且抗生素的全身性给药有时仅能够在感染部位实现抗生素药物的低血浆水平。例如，在有些情形下，如果感染是由耐药菌如耐甲氧西林的金黄色葡萄球菌(MRSA)引起的，这个问题则尤为严重。另外，目前已知的治疗糖尿病足感染的药品一般采用口服或注射头孢类、青霉类、万古霉类等抗菌素抗生素消炎药物，其缺陷是：毒副作用大、或极易产生耐药性，部分患者存在严重过敏反应等。因此，改进糖尿病足感染的治疗，尤其是在特定耐药菌感染的情况和/或患者遭受严重程度局部缺血的情况和/或骨组织受影响的情况下，显得尤为迫切和重要。
发明内容
本发明申请为了解决现有技术治疗糖尿病足感染的困境，提供了一种更切实有效的治疗方法。
一方面，本申请提供预防或治疗糖尿病足感染(DFI)、或者减轻所述DFI相关病症的方法，所述方法包括向有需要的患者施用外用治疗剂，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物，且所述DFI由革兰氏阳性菌感染引起，
在一些实施方案中，所述革兰氏阳性菌包含其耐药菌株。
在一些实施方案中，所述外用治疗剂为软膏制剂。
在一些实施方案中，所述外用治疗剂还包含聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂和抗氧剂的一种或多种。
在一些实施方案中，所述外用治疗剂由聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂、抗氧剂、以及式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物组成。
在一些实施方案中，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％。
在一些实施方案中，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％。
在一些实施方案中，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％。
在一些实施方案中，所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％。
在一些实施方案中，所述增溶剂的用量占总质量的约0.1％至约1％。
在一些实施方案中，所述抗氧剂的用量占总质量的约0.5％至约1％。
在一些实施方案中，所述外用治疗剂由下列所述的组分组成：以质量百分比总和为100％计，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％、所述聚乙二醇3350的用量占所述外用治疗剂 总质量的约28％至约33％、所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％、所述增溶剂的用量占所述外用治疗剂总质量的约0.1％至约1％、所述抗氧剂的用量占所述外用治疗剂总质量的约0.5％至约1％。
在一些实施方案中，所述方法包括以任选自下列所述的给药频率向所述有需要的患者施用所述外用治疗剂：每3天1次、每2天1次、每天1次和每天2次。
在一些实施方案中，所述糖尿病足感染由金黄色葡萄球菌感染和/或凝固酶阴性葡萄球菌感染引起。
在一些实施方案中，所述金黄色葡萄球菌包含其耐药菌株，且所述凝固酶阴性葡萄球菌包含其耐药菌株。
在一些实施方案中，所述方法还包括向所述有需要的患者施用有效量的其他治疗剂。
另一方面，本申请提供式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物在制备外用治疗剂中的用途，所述外用治疗剂用于预防或治疗糖尿病足感染(DFI)或者减轻所述DFI相关病症，且所述DFI由革兰氏阳性菌感染引起；其中，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物。
在一些实施方案中，所述革兰氏阳性菌包含其耐药菌株。
在一些实施方案中，所述外用治疗剂为软膏制剂。
在一些实施方案中，所述外用治疗剂还包含聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂和抗氧剂的一种或多种。
在一些实施方案中，所述外用治疗剂由聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂、抗氧剂、以及式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物组成。
在一些实施方案中，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％。
在一些实施方案中，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％。
在一些实施方案中，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％。
在一些实施方案中，所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％。
在一些实施方案中，所述增溶剂的用量占总质量的约0.1％至约1％。
在一些实施方案中，所述抗氧剂的用量占总质量的约0.5％至约1％。
在一些实施方案中，所述外用治疗剂由下列所述的组分组成：以质量百分比总和为100％计，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％、所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％、所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％、所述增溶剂的用量占所述外用治疗剂总质量的约0.1％至约1％、所述抗氧剂的用量占所述外用治疗剂总质量的约0.5％至约1％。
在一些实施方案中，所述外用治疗剂被配制成适于以任选自下列所述的给药频率施用于有需要的患者：每3天1次、每2天1次、每天1次和每天2次。
在一些实施方案中，所述糖尿病足感染由金黄色葡萄球菌感染和/或凝固酶阴性葡萄球菌感染引起。
在一些实施方案中，所述金黄色葡萄球菌包含其耐药菌株，且所述凝固酶阴性葡萄球菌包含其耐药菌株。
在一些实施方案中，所述外用治疗剂被配制成适于与有效量的其他治疗剂共同施用于所述有需要的患者。
具体实施方式
以下由特定的具体实施例说明本申请发明的实施方式，熟悉此技术的人士可由本说明书所公开的内容容易地了解本申请发明的其他优点及效果。
术语定义
在本申请中，术语“有需要的患者”通常可包括接受预防性或治疗性治疗的人类患者和其它哺乳动物对象包括但不限于非人类灵长类动物、实验动物如兔子、犬类、大鼠和小鼠、以及其它动物。这些“有需要的患者”示例性地可以是患有确诊的特定疾病的对象、正在接受特定疾病相关治疗的对象、有发展成特定疾病的趋势或风险的对象等。
在本申请中，术语“施用”通常是指通过任意引入或递送途径将所述药物或包含所述药物的组合物(例如，本申请的治疗剂)引入患者的身体中。可以采用本领域技术人员已知的用于使细胞、器官或组织与所述药物或其组合物接触的任何方法。
在本申请中，术语“治疗剂”通常是指当适当施用患者时能够诱导所需治疗效果、预防 产生某种病症、或使相关病症减轻的化合物、化合物的混合物、组合物、生物大分子或由生物材料制成的提取物。
在本申请中，术语“药学上可接受的盐”通常是指保留母体化合物(例如式(I)所示的化合物)的生物学效能和性质的常规酸-或碱-加成盐。仅作为示例，酸-加成盐可以由适合的非毒性的有机或无机酸形成，样品酸-加成盐包括从无机酸诸如盐酸、氢溴酸、氢碘酸、硫酸、氨基磺酸、磷酸和硝酸等衍生的那些，和从有机酸诸如对-甲苯磺酸、萘磺酸、萘二磺酸、甲磺酸、乙磺酸、三氟乙酸等衍生的那些；碱-加成盐包括从无机碱衍生出的诸如钠盐、钾盐、锂盐、铵盐、钙盐和镁盐，和从有机碱衍生的诸如伯胺、仲胺和叔胺的盐。将(药物)化合物化学修饰成盐对于药物化学家是众所周知的技术，以获得化合物的改进的物理和化学稳定性、吸湿性、流动性和溶解度。参见，例如，Ansel，H.，等，Pharmaceutical Dosage Forms and Drug Delivery Systems，6th ed.，1995。
在本申请中，术语“溶剂化物”和“溶剂合物”可互换使用，其通常是指一个或多个溶剂分子与本申请的盐型化合物的缔合物或复合物。形成溶剂合物的溶剂的例子包括但不限于水、异丙醇、乙醇、甲醇、DMSO、乙酸乙酯、乙酸和乙醇胺。术语“水合物”通常是指其中的溶剂分子是水的复合物。
在本申请中，术语“前药”通常是指该前药物质在对患者施用并且之后可以代谢形成具有本申请化合物结构的物质；术语“代谢产物”通常是指本申请的化合物在对患者施用并且之后代谢得到的物质，这类衍生物所包含的前药和代谢产物包括在本申请发明的范围内。
在本申请中，术语“氘代物”和“氘代化合物”可互换使用，其通常是指有机化合物中的一个或多个氢原子被氘原子取代后获得的新化合物。
在本申请中，术语“软膏制剂”通常是指药物和油脂性或水溶性基质混合制成的均匀的半固体外用制剂。其因为药物在所述基质中的分散状态不同可分为溶液型软膏剂和混悬型软膏剂，其中溶剂型软膏剂为药物溶解或共溶于基质或基质组分中而制成的软膏剂型，而混悬型软膏剂为药物细粉均匀分散于基质中而制成的软膏剂型。本申请所提供的软膏制剂通常用于外用和局部治疗，在某些实施方案中，软膏制剂中的药物(例如，本申请所述的式(I)化合物)经透皮吸收后可发挥全身的药理或治疗作用。在某些实施方案中，软膏剂型的基质作为赋形剂和药物载体，可对软膏剂的质量和药物的释放与吸收产生重要影响。本领域常见的软膏剂型的基质可分为油脂性基质、乳剂基质和水溶性基质。可采用本领域适合的制备方法和工艺获得本申请治疗方法所需要的软膏剂型。
在本申请中，术语“选自”通常是指包括选择的对象以及其所有组合。例如“选自(：)A、B和C”意指包括A、B和C的所有组合，例如，A、B、C、A+B、A+C、B+C或A+B+C。
在本申请中，术语“有效量”或“有效剂量”可互换地使用，通常是指足够获得或至少部分获得预期疗效的量，当用于有需要的患者时，其通常是指足够使一个已经患病的病人治愈或至少部分阻止该病及其并发症的量。对于这种用途有效的量将依赖于所述病人感染的严重程度和病人自身免疫系统的整体状态。
在本申请中，术语“共同施用”通常是指本申请所述的治疗剂与其他治疗剂或药物作为一个单一制剂或作为多个独立制剂的施用。共同施用可以是同时进行的或以任何顺序相继进行的，例如，可优选在两种(或所有)药物活性成分同时发挥其生物活性时持续一定的时间段。所述本申请的治疗剂和其他治疗剂不一定由相同的施用途径施用。
在本申请中，术语“约”或“大约”通常由本领域普通技术人员确定的针对特定值的可接受误差范围内，其部分取决于怎样测量或确定该值，即，测量系统的限制。例如，“约”或“大约”可意指按照本领域的实践在1或超过1个标准偏差内。或者，“约”或“大约”可意指至多10％或20％的范围(即，±10％或±20％)。例如，约3mg可包括2.7mg和3.3mg之间(对于10％)或2.4mg和3.6mg之间(对于20％)的任何数量。此外，特别是关于生物学系统或过程，该术语可意指至多一个数量级的值或至多5倍的值。当具体的值或组合物在本说明书和所附权利要求书中提供时，除了另外说明，“约”或“大约”的含义应假定在对于该具体的值或组合物可接受的误差范围内。
发明详述
一方面，本申请提供预防或治疗糖尿病足感染(DFI)、或者减轻所述DFI相关病症的方法，所述方法包括向有需要的患者施用外用治疗剂，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物，且所述DFI由革兰氏阳性菌感染引起。在一些实施方案中，所述革兰氏阳性菌可包含其耐药菌株。
在一些实施方案中，所述糖尿病足感染由金黄色葡萄球菌感染和/或凝固酶阴性葡萄球菌感染引起。例如，所述金黄色葡萄球还可包含其耐药菌株，且所述凝固酶阴性葡萄球菌还可包含其耐药菌株。具体地，所述凝固酶阴性葡萄球菌可选自表皮葡萄球菌、腐生葡萄球菌、木葡萄球菌、溶血葡萄球菌、头状葡萄球菌、华纳葡萄球菌、模仿葡萄球菌、木糖葡萄球菌和猿类葡萄球菌。在本申请中，所述耐药菌株可以是抗利福霉素(例如，利福平)单耐药的、抗喹诺酮或喹嗪酮单耐药的、或者抗利福霉素和喹嗪酮双耐药的。例如，所述耐药菌株还可 以是对其他抗生素耐药的，其中包括对大环内酯类药物如克拉霉素、阿奇霉素、罗红霉素等耐药；对硝基咪唑类药物如甲硝唑、奥硝唑、普瑞玛尼、德拉马尼等耐药；对氨基糖苷类药物如链霉素、阿米卡星等耐药；对β-内酰胺类药物如甲氧西林、氨苄西林、阿莫西林等耐药；对四环素类药物如四环素、替加环素、米诺环素等耐药；对恶唑烷酮类药物如利奈唑胺、特地唑胺等耐药；对硝基呋喃类药物如呋喃唑酮等耐药；对多肽类药物如万古霉素、多粘菌素等耐药；对二芳基喹啉类药物如贝达喹啉耐药以及氯法齐明耐药等。
在一些实施方案中，所述外用治疗剂可为软膏制剂。
在一些实施方案中，所述外用治疗剂还包含聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂和抗氧剂的一种或多种。例如，所述外用治疗剂由聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂、抗氧剂、以及式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物组成。优选的，本申请所述的增溶剂可包括三乙醇胺。优选的，本申请所述的抗氧化剂可包括维生素C、维生素E或它们的组合。
在一些实施方案中，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％。例如，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％或约0.70％。
在一些实施方案中，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％。例如，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％、约56％、约57％、约58％、约59％或约60％。
在一些实施方案中，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％。例如，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％、约29％、约30％、约31％、约32％或约33％。
在一些实施方案中，所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％。例如，所述丙二醇的用量占所述外用治疗剂总质量的约8.0％、约8.5％、约9.0％、约9.5％、约10.0％、约10.5％、约11.0％、约11.5％或约12.0％。
在一些实施方案中，所述增溶剂的用量占总质量的约0.1％至约1％。例如，所述增溶剂的用量占总质量的约0.10％、约0.15％、约0.20％、约0.25％、约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％。
在一些实施方案中，所述抗氧剂的用量占总质量的约0.5％至约1％。例如，所述抗氧剂的用量占总质量的约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％。
优选的，在一些实施方案中，所述外用治疗剂由下列所述的组分组成：以质量百分比总和为100％计，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％(例如，约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％或约0.70％)，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％(例如，约55％、约56％、约57％、约58％、约59％或约60％)、所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％(例如，约28％、约29％、约30％、约31％、约32％或约33％)、所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％(例如，约8.0％、约8.5％、约9.0％、约9.5％、约10.0％、约10.5％、约11.0％、约11.5％或约12.0％)、所述增溶剂的用量占所述外用治疗剂总质量的约0.1％至约1％(例如，约0.10％、约0.15％、约0.20％、约0.25％、约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％)、所述抗氧剂的用量占所述外用治疗剂总质量的约0.5％至约1％(例如，约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％)。
在一些实施方案中，所述方法包括以任选自下列所述的给药频率向所述有需要的患者施用所述外用治疗剂：每3天1次、每2天1次、每天1次和每天2次。
在一些实施方案中，所述方法还包括向所述有需要的患者施用有效量的其他治疗剂。例如，所述方法还包括通过注射给药(例如，静脉注射、肌肉注射和/或皮下注射)、口服给药、腔内给药、肠内给药和/或透皮吸收向所述患者施用有效量的其他治疗剂。例如，所述其他治疗剂可选自抗菌剂、麻醉剂、镇痛药、镇静药、激素药、抗炎药、抗凝剂、血小板聚集抑制剂、退热剂、细胞膜渗透剂和肌松药等。
另一方面，本申请提供式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物在制备外用治疗剂中的用途，所述外用治疗剂用于预防或治疗糖尿病足感染(DFI)或者减轻所述DFI相关病症，且所述DFI由革兰氏阳性菌感染引起；其中，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物。在一些实施方案中，所述革兰氏阳性菌包含其耐药菌株。
在一些实施方案中，所述糖尿病足感染由金黄色葡萄球菌感染和/或凝固酶阴性葡萄球菌 感染引起。例如，所述金黄色葡萄球还可包含其耐药菌株，且所述凝固酶阴性葡萄球菌还可包含其耐药菌株。具体地，所述凝固酶阴性葡萄球菌可选自表皮葡萄球菌、腐生葡萄球菌、木葡萄球菌、溶血葡萄球菌、头状葡萄球菌、华纳葡萄球菌、模仿葡萄球菌、木糖葡萄球菌和猿类葡萄球菌。在本申请中，所述耐药菌株可以是抗利福霉素(例如，利福平)单耐药的、抗喹诺酮或喹嗪酮单耐药的、或者抗利福霉素和喹嗪酮双耐药的。例如，所述耐药菌株还可以是对其他抗生素耐药的，其中包括对大环内酯类药物如克拉霉素、阿奇霉素、罗红霉素等耐药；对硝基咪唑类药物如甲硝唑、奥硝唑、普瑞玛尼、德拉马尼等耐药；对氨基糖苷类药物如链霉素、阿米卡星等耐药；对β-内酰胺类药物如甲氧西林、氨苄西林、阿莫西林等耐药；对四环素类药物如四环素、替加环素、米诺环素等耐药；对恶唑烷酮类药物如利奈唑胺、特地唑胺等耐药；对硝基呋喃类药物如呋喃唑酮等耐药；对多肽类药物如万古霉素、多粘菌素等耐药；对二芳基喹啉类药物如贝达喹啉耐药以及氯法齐明耐药等。
在一些实施方案中，所述外用治疗剂可为软膏制剂。
在一些实施方案中，所述外用治疗剂还包含聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂和抗氧剂的一种或多种。例如，所述外用治疗剂由聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂、抗氧剂、以及式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物组成。优选的，本申请所述的增溶剂可包括三乙醇胺。优选的，本申请所述的抗氧化剂可包括维生素C、维生素E或它们的组合。
在一些实施方案中，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％。例如，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％或约0.70％。
在一些实施方案中，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％。例如，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％、约56％、约57％、约58％、约59％或约60％。
在一些实施方案中，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％。例如，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％、约29％、约30％、约31％、约32％或约33％。
在一些实施方案中，所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％。例如，所述丙二醇的用量占所述外用治疗剂总质量的约8.0％、约8.5％、约9.0％、约9.5％、约 10.0％、约10.5％、约11.0％、约11.5％或约12.0％。
在一些实施方案中，所述增溶剂的用量占总质量的约0.1％至约1％。例如，所述增溶剂的用量占总质量的约0.10％、约0.15％、约0.20％、约0.25％、约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％。
在一些实施方案中，所述抗氧剂的用量占总质量的约0.5％至约1％。例如，所述抗氧剂的用量占总质量的约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％。
优选的，在一些实施方案中，所述外用治疗剂由下列所述的组分组成：以质量百分比总和为100％计，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％(例如，约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％或约0.70％)，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％(例如，约55％、约56％、约57％、约58％、约59％或约60％)、所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％(例如，约28％、约29％、约30％、约31％、约32％或约33％)、所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％(例如，约8.0％、约8.5％、约9.0％、约9.5％、约10.0％、约10.5％、约11.0％、约11.5％或约12.0％)、所述增溶剂的用量占所述外用治疗剂总质量的约0.1％至约1％(例如，约0.10％、约0.15％、约0.20％、约0.25％、约0.30％、约0.35％、约0.40％、约0.45％、约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％)、所述抗氧剂的用量占所述外用治疗剂总质量的约0.5％至约1％(例如，约0.50％、约0.55％、约0.60％、约0.65％、约0.70％、约0.75％、约0.80％、约0.85％、约0.90％、约0.95％或约1.00％)。
在一些实施方案中，所述外用治疗剂被配制成适于以任选自下列所述的给药频率施用于有需要的患者：每3天1次、每2天1次、每天1次和每天2次。
在一些实施方案中，所述外用治疗剂被配制成适于与有效量的其他治疗剂共同施用于所述有需要的患者。例如，所述外用治疗剂可被配制成适于与有效量的其他治疗剂共同施用于所述有需要的患者，其中，所述其他治疗剂可通过注射给药(例如，静脉注射、肌肉注射和/或皮下注射)、口服给药、腔内给药、肠内给药和/或透皮吸收施用于所述患者。例如，所述其他治疗剂可选自抗菌剂、麻醉剂、镇痛药、镇静药、激素药、抗炎药、抗凝剂、血小板聚集抑制剂、退热剂、细胞膜渗透剂和肌松药等。
不欲被任何理论所限，下文中的实施例仅仅是为了阐释本申请的方法和用途等，而不用于限制本申请发明的范围。
实施例
实施例1
式(I)化合物对糖尿病足感染(DFI)临床分离菌株的生物膜抗菌活性测定
1.实验方法
受试菌株的准备：本实施例收集了49例II型糖尿患者的足部标本。在上述标本中，通过匀浆，涂板，37℃培养得到分离菌株，并去除真菌、长势不佳或无法分离纯化的菌株后，总共获得69株临床菌株，其中革兰氏阳性菌55株，革兰氏阴性菌14株；革兰氏阳性菌中，葡萄球菌43株，金黄色葡萄球菌18株，表皮葡萄球菌8株，路邓葡萄球菌5株。另取1株ATCC标准菌株作为标准和质控菌株。
生物膜的制备：在无菌环境中用接种环挑取经过鉴定且复苏的单个菌落，配置成0.5麦氏浊度单位的菌悬液，作为初始接种菌悬液。将初始接种菌悬液进行1:200倍稀释：10mL CAMHB培养基中加入50μL的初始接种菌悬液。用移液枪移取150μL的接种菌悬液至CBD板中，将接种好的CBD板置于35±2℃孵箱中孵育16～20小时。
抗菌活性测定：采用标准肉汤稀释法及文献报道的体外生物膜培养和药敏方法，评价式(I)化合物以及对照药物(详见2)对从临床分离的69株糖尿病足感染临床菌株的最低抑菌浓度(MIC)和体外生物膜的最低清除生物膜浓度(MBBC)。
2.结果分析
表1-1式(I)化合物和对照药物对DFI临床分离菌株的MIC和生物膜的MBBC(μg/mL)结果汇总(革兰氏阳性菌vs.革兰氏阴性菌)

表1-1的结果表明，式(I)化合物对革兰氏阳性菌分离株具有相较于革兰氏阴性菌明显更优的抑菌活性，(1)其MIC50和MIC90分别为≤0.015μg/mL和0.25μg/mL，且明显优于临床一线用药利奈唑胺(MIC50和MIC90分别为2μg/mL和4μg/mL)和万古霉素(MIC50和MIC90均为2μg/mL)；(2)式(I)化合物的MBBC结果同样证明其对革兰氏阳性菌体外生物膜具有相较于革兰氏阴性菌更好的杀菌活性，其MBBC50和MBBC90分别为0.125μg/mL和16μg/mL，明显优于临床一线用药利奈唑胺(MBBC50和MBBC90均>128μg/mL)和万古霉素(MBBC50和MBBC90均>128μg/mL)。
表1-2式(I)化合物和对照药物对DFI临床分离菌株的MIC(μg/mL)结果汇总(代表性革兰氏阳性菌)
表1-3式(I)化合物和对照药物对DFI临床分离菌株生物膜的MBBC(μg/mL)结果汇总(代表性革兰氏阳性菌)
表1-2的结果显示，式(I)化合物对葡萄球菌(包括金黄色葡萄球菌和表皮葡萄球菌在 内)分离株具有较好的抑菌活性，它们的MIC区间分别为≤0.015-0.25μg/mL、≤0.015-0.03μg/mL和≤0.015-0.03μg/mL，式(I)化合物对葡萄球菌、金黄色葡萄球菌的MIC50均≤0.015μg/mL，明显优于利奈唑胺(MIC50均为2μg/mL)和万古霉素(MIC50均为2μg/mL)；其MIC90均≤0.015μg/mL，明显优于利奈唑胺(MIC90均为4μg/mL)和万古霉素(MIC90均为2μg/mL)。
表1-3的结果显示，式(I)化合物对葡萄球菌(包括金黄色葡萄球菌和表皮葡萄球菌在内)体外生物膜具有较好的杀菌活性，它们的MBBC区间分别为≤0.015-1μg/mL、0.03-0.5μg/mL和≤0.015-0.06μg/mL，式(I)化合物对葡萄球菌、金黄色葡萄球菌的MBBC50分别为0.06μg/mL、0.25μg/mL，明显优于利奈唑胺(MBBC50均为>128μg/mL)和万古霉素(MBBC50均为>128μg/mL)；其MBBC90均为0.5μg/mL，明显优于利奈唑胺(MBBC90均为>128μg/mL)和万古霉素(MBBC90均为>128μg/mL)。
以上结果整体上表明了式(I)化合物对革兰氏阳性菌以及革兰氏阳性菌中的葡萄球菌(包括金黄色葡萄球菌和表皮葡萄球菌在内)分离株和体外生物膜均有很好的抑菌和杀菌活性，并且抑菌和杀菌活性明显优于临床一线用药利奈唑胺和万古霉素，其用于糖尿病足感染治疗具有潜在的临床优势。
实施例2
本申请治疗方法用于小鼠金黄色葡萄球菌皮肤感染模型的药效学评价
1.实验方法
本实施例使用S.aureus NRS 384构建稳定的小鼠皮肤感染模型，用以评估本申请所述的包含式(I)化合物的软膏剂在皮肤表面的抗菌活性。本实施例共设立6组，分别为：空白对照组(以感染4小时后为实验终点)、溶媒组、百多邦软膏组、包含低、中、高三种剂量式(I)化合物的软膏组，以上的每组有8只动物，具体实验设置如下：

2.结果分析
感染后72小时对各治疗组动物在无菌操作环境下进行小鼠皮肤采样，并置于装有5mL无菌注射用生理盐水的15mL离心管中，使用均质匀浆器进行匀浆约1min，吸取200μL匀浆液用无菌注射用生理盐水从100～10-5倍进行稀释，每个稀释梯度取10μL点板，放置35±2℃培养箱培养过夜，次日进行CFU计数。
表2小鼠皮肤载菌量计数结果

注：***与模型组比，p＜0.001，具极显著性差异；*与模型组比，0.01<p<0.05，具显著差
异；采用one-way ANOVA分析方法。
本次药效实验结果显示，与溶媒组的皮肤载菌量9.154±0.2 73log相比，经百多邦软膏(2％莫匹罗星)治疗后的小鼠皮肤载菌量下降了2.119个log值，表明其具有良好的杀菌作用；分别经0.5％、0.05％和0.005％含量的式(I)化合物软膏治疗的小鼠，其皮肤载菌量分别下降了4.718个log值、3.100个log值和1.063个log值，表明高剂量组(0.5％)和中剂量组(0.05％)的软膏在该皮肤感染模型中展现出良好的杀菌效果，与溶媒组动物相比具极显著差异，且优于百多邦软膏治疗组，进一步证明其用于糖尿病足感染治疗具有潜在的临床优势。

Claims (32)

  1. 预防或治疗糖尿病足感染(DFI)、或者减轻所述DFI相关病症的方法，所述方法包括向有需要的患者施用外用治疗剂，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物，且所述DFI由革兰氏阳性菌感染引起，
  2. 根据权利要求1所述的方法，所述革兰氏阳性菌包含耐药菌株。
  3. 根据权利要求1-2中任一项所述的方法，所述外用治疗剂为软膏制剂。
  4. 根据权利要求1-3中任一项所述的方法，所述外用治疗剂还包含聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂和抗氧剂的一种或多种。
  5. 根据权利要求1-4中任一项所述的方法，所述外用治疗剂由聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂、抗氧剂、以及式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物组成。
  6. 根据权利要求1-5中任一项所述的方法，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％。
  7. 根据权利要求1-6中任一项所述的方法，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％。
  8. 根据权利要求1-7中任一项所述的方法，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％。
  9. 根据权利要求1-8中任一项所述的方法，所述丙二醇的用量占所述外用治疗剂总质量的约 8％至约12％。
  10. 根据权利要求1-9中任一项所述的方法，所述增溶剂的用量占总质量的约0.1％至约1％。
  11. 根据权利要求1-10中任一项所述的方法，所述抗氧剂的用量占总质量的约0.5％至约1％。
  12. 根据权利要求1-11中任一项所述的方法，所述外用治疗剂由下列所述的组分组成：
    以质量百分比总和为100％计，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％、所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％、所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％、所述增溶剂的用量占所述外用治疗剂总质量的约0.1％至约1％、所述抗氧剂的用量占所述外用治疗剂总质量的约0.5％至约1％。
  13. 根据权利要求1-12中任一项所述的方法，所述方法包括以任选自下列所述的给药频率向所述有需要的患者施用所述外用治疗剂：每3天1次、每2天1次、每天1次和每天2次。
  14. 根据权利要求1-13中任一项所述的方法，所述糖尿病足感染由金黄色葡萄球菌感染和/或凝固酶阴性葡萄球菌感染引起。
  15. 根据权利要求14所述的方法，所述金黄色葡萄球菌包含其耐药菌株，且所述凝固酶阴性葡萄球菌包含其耐药菌株。
  16. 根据权利要求1-15中任一项所述的方法，所述方法还包括向所述有需要的患者施用有效量的其他治疗剂。
  17. 式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物在制备外用治疗剂中的用途，所述外用治疗剂用于预防或治疗糖尿病足感染(DFI)或者减轻所述DFI相关病症，且所述DFI由革兰氏阳性菌感染引起；其中，所述外用治疗剂包含式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物。
  18. 根据权利要求17所述的用途，所述革兰氏阳性菌包含其耐药菌株。
  19. 根据权利要求17-18中任一项所述的用途，所述外用治疗剂为软膏制剂。
  20. 根据权利要求17-19中任一项所述的用途，所述外用治疗剂还包含聚乙二醇400、聚乙二醇3350、丙二醇、增溶剂和抗氧剂的一种或多种。
  21. 根据权利要求17-20中任一项所述的用途，所述外用治疗剂由聚乙二醇400、聚乙二醇 3350、丙二醇、增溶剂、抗氧剂、以及式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物组成。
  22. 根据权利要求17-21中任一项所述的用途，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％。
  23. 根据权利要求17-22中任一项所述的用途，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％。
  24. 根据权利要求17-23中任一项所述的用途，所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％。
  25. 根据权利要求17-24中任一项所述的用途，所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％。
  26. 根据权利要求17-25中任一项所述的用途，所述增溶剂的用量占总质量的约0.1％至约1％。
  27. 根据权利要求17-26中任一项所述的用途，所述抗氧剂的用量占总质量的约0.5％至约1％。
  28. 根据权利要求17-27中任一项所述的用途，所述外用治疗剂由下列所述的组分组成：
    以质量百分比总和为100％计，所述式(I)所示的化合物和/或其药学上可接受的盐、水合物、溶剂化物、前药、代谢产物或氘代物的用量占所述外用治疗剂总质量的约0.3％至约0.7％，所述聚乙二醇400的用量占所述外用治疗剂总质量的约55％至约60％、所述聚乙二醇3350的用量占所述外用治疗剂总质量的约28％至约33％、所述丙二醇的用量占所述外用治疗剂总质量的约8％至约12％、所述增溶剂的用量占所述外用治疗剂总质量的约0.1％至约1％、所述抗氧剂的用量占所述外用治疗剂总质量的约0.5％至约1％。
  29. 根据权利要求17-28中任一项所述的用途，所述外用治疗剂被配制成适于以任选自下列所述的给药频率施用于有需要的患者：每3天1次、每2天1次、每天1次和每天2次。
  30. 根据权利要求17-29中任一项所述的用途，所述糖尿病足感染由金黄色葡萄球菌感染和/或凝固酶阴性葡萄球菌感染引起。
  31. 根据权利要求30所述的用途，所述金黄色葡萄球菌包含其耐药菌株，且所述凝固酶阴性葡萄球菌包含其耐药菌株。
  32. 根据权利要求17-31中任一项所述的用途，所述外用治疗剂被配制成适于与有效量的其他治疗剂共同施用于所述有需要的患者。
PCT/CN2023/100595 2023-06-16 2023-06-16 化合物治疗疾病的方法及其用途 Ceased WO2024254841A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2025572332A JP2026521250A (ja) 2023-06-16 2023-06-16 化合物による疾患治療方法及びその使用
CN202380099437.2A CN121419767A (zh) 2023-06-16 2023-06-16 化合物治疗疾病的方法及其用途
PCT/CN2023/100595 WO2024254841A1 (zh) 2023-06-16 2023-06-16 化合物治疗疾病的方法及其用途
EP23941076.4A EP4729057A4 (en) 2023-06-16 2023-06-16 METHOD OF TREATING A DISEASE USING A COMPOUND AND USE OF A COMPOUND

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2023/100595 WO2024254841A1 (zh) 2023-06-16 2023-06-16 化合物治疗疾病的方法及其用途

Publications (1)

Publication Number Publication Date
WO2024254841A1 true WO2024254841A1 (zh) 2024-12-19

Family

ID=93851179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/100595 Ceased WO2024254841A1 (zh) 2023-06-16 2023-06-16 化合物治疗疾病的方法及其用途

Country Status (4)

Country Link
EP (1) EP4729057A4 (zh)
JP (1) JP2026521250A (zh)
CN (1) CN121419767A (zh)
WO (1) WO2024254841A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115501230B (zh) * 2022-08-05 2023-11-21 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子软膏剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031572A (zh) * 2004-07-22 2007-09-05 坎布里制药公司 (r/s)利福霉素衍生物，它们的制备和药物组合物
CN109464673A (zh) * 2019-01-08 2019-03-15 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其盐的应用和制剂
CN109529045A (zh) * 2019-01-08 2019-03-29 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其药学上可接受的盐的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115501230B (zh) * 2022-08-05 2023-11-21 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子软膏剂及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031572A (zh) * 2004-07-22 2007-09-05 坎布里制药公司 (r/s)利福霉素衍生物，它们的制备和药物组合物
CN109464673A (zh) * 2019-01-08 2019-03-15 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其盐的应用和制剂
CN109529045A (zh) * 2019-01-08 2019-03-29 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其药学上可接受的盐的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANSEL, H. ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995
See also references of EP4729057A4
ZHENKUN MA, ANTHONY SIMON LYNCH: "Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 59, no. 14, 28 July 2016 (2016-07-28), US , pages 6645 - 6657, XP055718162, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00485 *
周莹等 (ZHOU, YING ET AL.): "糖尿病足的病原菌分布与耐药性分析 (Distribution and Drug Resistance of Pathogens Causing Diabetic Foot Infections)", 中华医院感染学杂志 (CHINESE JOURNAL OF NOSOCOMIOLOGY), vol. 23, no. 19, 31 October 2013 (2013-10-31), XP009559499 *

Also Published As

Publication number Publication date
JP2026521250A (ja) 2026-06-29
EP4729057A1 (en) 2026-04-22
EP4729057A4 (en) 2026-07-22
CN121419767A (zh) 2026-01-27

Similar Documents

Publication Publication Date Title
CN114099492B (zh) 天然药物在制备抗菌药物中的应用
US20040198704A1 (en) Compositions and method for treating microbial and parasitic infections in cattle and other animals
US11826325B2 (en) Use of Belinostat or pharmaceutically acceptable salt thereof in preparation of drug for treating infection
CN121419767A (zh) 化合物治疗疾病的方法及其用途
EP3993796B1 (en) Combination for the treatment of infections caused by mycoplasma genitalium
EP4192247A1 (en) Antibacterial compositions and methods for fabricating thereof
CN101543506A (zh) 预防或治疗猪链球菌病的复方抗生素组合物
CN106902116B (zh) 一种利福霉素-喹嗪酮双靶标分子的应用
CN119633098A (zh) 硫唑烷基脲类化合物和多粘菌素的组合物及其在制备抗沙门氏菌感染药物上的应用
WO2019148575A1 (zh) 一种吡啶类化合物的新用途
BRPI0918593B1 (pt) composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas
CN110946870A (zh) 一种抗菌药物组合物及其应用
CN112438975B (zh) 糖尿病治疗药物在抑菌中的应用
CN109620827B (zh) 杂环丙烯酮类化合物作为抗菌剂的用途
WO2024254840A1 (zh) 化合物治疗疾病的方法及其用途
CN102138925B (zh) 替加环素组合物及其制备方法
TW202446395A (zh) 關節腔給藥方法及其用途
CN102805866B (zh) 一种兽用药物制剂及其应用
BR112012006250B1 (pt) composições para tratar infecções bacterianas usando ceftaroline
CN100344282C (zh) 一种利福霉素钠注射液的生产方法
CN113456641B (zh) 一种化合物在制备抗真菌药物中的应用
WO2017118994A1 (en) A freeze dried parenteral composition of tigecycline and process for preparation thereof
WO2024221160A1 (zh) 化合物治疗关节假体周围感染的方法
CN103330711B (zh) 注射用氟氯西林钠阿莫西林钠
WO2019126910A1 (zh) 含有哌拉西林的组合物、其药物制剂及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23941076

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025572332

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023941076

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023941076

Country of ref document: EP

Effective date: 20260116

ENP Entry into the national phase

Ref document number: 2023941076

Country of ref document: EP

Effective date: 20260116

ENP Entry into the national phase

Ref document number: 2023941076

Country of ref document: EP

Effective date: 20260116

ENP Entry into the national phase

Ref document number: 2023941076

Country of ref document: EP

Effective date: 20260116

WWP Wipo information: published in national office

Ref document number: 2023941076

Country of ref document: EP